540787-75-5

Basic information

• Product Name: (3S)-1-(2-AMINOETHYL)-3-PYRROLIDINOL
• Synonyms: (3S)-1-(2-AMINOETHYL)-3-PYRROLIDINOL;3-Pyrrolidinol,1-(2-aminoethyl)-,(3S)-(9CI);(3S)-1-(2-aMinoethyl)pyrrolidin-3-ol;(3S)-1-(2-Aminoethyl)pyrrolidin-3-ol dihydrochloride;(3S)-1-(2-Aminoethyl)-3-pyrrolidinol dihydrochloride
• CAS NO: 540787-75-5
• Molecular Formula: C6H14N2O
• Molecular Weight: 130.19
• Product Categories: AMINETERTIARY;PYRROLIDINE;pharmacetical
• Mol File: 540787-75-5.mol

Chemical Properties

• Boiling Point: 245.3 °C at 760 mmHg
• Flash Point: 102.1 °C
• Appearance: /
• Density: 1.103 g/cm³
• Vapor Pressure: 0.00482mmHg at 25°C
• Refractive Index: 1.53
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: (3S)-1-(2-AMINOETHYL)-3-PYRROLIDINOL(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-1-(2-AMINOETHYL)-3-PYRROLIDINOL(540787-75-5)
• EPA Substance Registry System: (3S)-1-(2-AMINOETHYL)-3-PYRROLIDINOL(540787-75-5)

Safety Data

• Hazardous Substances Data: 540787-75-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3S)-1-(2-Aminoethyl)-3-pyrrolidinol is used as a chiral auxiliary in organic synthesis for its ability to induce asymmetry in chemical reactions, leading to the production of enantiomerically pure compounds. This is crucial in the synthesis of pharmaceuticals where stereochemistry plays a significant role in the compound's activity and efficacy.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (3S)-1-(2-Aminoethyl)-3-pyrrolidinol serves as a building block for the synthesis of various drugs and biologically active compounds. Its chiral nature allows for the creation of molecules with specific biological activities, which is essential for the development of new drug entities.
Used in Asymmetric Catalysis:
(3S)-1-(2-Aminoethyl)-3-pyrrolidinol is utilized in the preparation of chiral ligands for asymmetric catalysis. These ligands are vital in catalytic reactions that produce enantiomerically enriched products, which are important in the synthesis of chiral compounds with pharmaceutical relevance.
Used in Medicine:
In the medical field, (3S)-1-(2-Aminoethyl)-3-pyrrolidinol has potential applications due to its unique structure and properties. It may contribute to the development of new therapeutic agents or play a role in the enhancement of existing treatments.
Used in Agriculture:
(3S)-1-(2-Aminoethyl)-3-pyrrolidinol may also find use in agricultural applications, potentially in the development of new agrochemicals or as a component in the synthesis of compounds that can improve crop yields or protect against pests and diseases.
Used in Materials Science:
In materials science, the compound's unique structure could be leveraged to develop new materials with specific properties, such as chiral materials with applications in sensors, catalysts, or other advanced technologies.
Each of these applications underscores the importance of (3S)-1-(2-Aminoethyl)-3-pyrrolidinol as a versatile and valuable compound in the realms of chemistry, medicine, and beyond.

InChI:InChI=1/C6H14N2O/c7-2-4-8-3-1-6(9)5-8/h6,9H,1-5,7H2/t6-/m0/s1

Upstream product

• 540787-77-7 (S)-2-(3-hydroxypyrrolidin-1-yl)acetonitrile 

Downstream Products

• 857637-45-7 2-(3-chloropyrrolidin-1yl)ethanamine 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

PKM2 MODULATORS AND METHODS FOR THEIR USE

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein

SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG

To improve the ex vivo potency of MCH inhibitor 1a and to address its hERG liability, a structure-activity study was carried out, focusing on three regions of the lead structure. Introduction of new side chains with basic nitrogen improved in vitro and ex

ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS

Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R1 to R4 are each selected from the group consisting of H, C1-4 alkyl, X1, -NHR0N (R5)2 in which R0 is a C1-12 alkanediyl and each R5 is H or optionally substituted C1-4 alkyl, and a group of formula (II) in which at least one of R6,R7 and R8 is selected from X2 , and X2 substituted C1-4 alkyl and any others are H or C1-4 alkyl; R9 is selected from H, C1-4 alkyl, X2 and X2 substituted C1-4 alkyl; m is 0 or 1; n is 1 or 2; X1 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; and X2 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; provided that at least one of R1 to R4 is a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives. The amine compounds are cytotoxic and may be used as alkylating agents having topoisomerase II inhibiting activities in cancer therapy.